SC0191

DRUG2 trials

Sponsors

Biocity Biopharmaceutics Co., Ltd., Tianshu Liu

Conditions

Advanced Ovarian CancerMetastatic Colorectal CancerSerous Ovarian Cancer

Phase 1

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Biocity Biopharmaceutics Co., Ltd.Advanced Ovarian Cancer, Serous Ovarian Cancer

Start: 2023-10-30End: 2025-11-30Target: 112Updated: 2023-09-26

Phase 2

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

Not yet recruitingNCT06363552

Tianshu LiuMetastatic Colorectal Cancer

Start: 2024-05-31End: 2025-12-31Target: 36Updated: 2024-04-12

Related Papers

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies.

2025-11-30

Abstract 2908: WEE1 as a therapeutic target in <i>TP53</i> and <i>ARID1A</i> concurrent mutant colorectal cancers

Cancer Research2025-04-211 citations